Delivery Order SPE2DB24D2216-SPE2DB25FGPTS
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count packaging). This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,374.19 and is scheduled for completion by September 4, 2025. The contract represents a continuation of AmerisourceBergen's role as a critical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order by the Defense Logistics Agency on August 18, 2025, for the supply of dapagliflozin 10 mg tablets in quantities of 30 units. The contract carries a firm fixed price ceiling value of $39,193.68 and is scheduled for completion by August 19, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract value of $4,353.54 and completion deadline of September 10, 2025. This non-set-aside, firm fixed-price delivery order represents a continuation of AmerisourceBergen's substantial role as a pharmaceutical supplier to the federal government. The award is executed under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract value of $1,008.03 and a firm fixed price structure. This non-set-aside competitive award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance...
- The Defense Logistics Agency awarded a $1,329.27 delivery order to AmerisourceBergen Drug Corp for Dapagliflozin 10 mg tablets (30-count packaging) with an ultimate completion date of September 3, 2025. This is a firm fixed price, non-set-aside contract awarded on September 2, 2025, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $2,356.02 delivery order to AmerisourceBergen Drug Corp for Dapagliflozin 5 mg tablets (30-count units) on September 11, 2025, with completion targeted for September 12, 2025. This is a firm fixed-price, non-set-aside contract performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 5 mg tablets in quantities of 30 units, with a ceiling value of $8,774.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count package) under a firm fixed-price contract valued at $1,722.16. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to take place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPTSDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 10, 2025, for Dapagliflozin 10 mg tablets (30-count packaging) with a ceiling value of $91,388.22. This firm fixed-price contract, which carries an ultimate completion date of September 11, 2025, was competitively awarded without set-aside designation by the Defense Logistics Agency (DLA), a defense-focused federal procurement entity. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical prime vendor contract enables the company to supply a broad range of medications and medical supplies to support military healthcare programs globally, including products for the Defense Health Agency and U.S. Coast Guard. The current award for Dapagliflozin—a diabetes medication—exemplifies the company's role in fulfilling federal medical supply requirements through its established relationship with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $91.4k | 9/10/25 |